Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells
Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment. However, several clinical trials demonstrate that monotherapy with abemaciclib has no obv...
Na minha lista:
| Principais autores: | , , , |
|---|---|
| 格式: | Artigo |
| 语言: | Inglês |
| 出版: |
Frontiers Media S.A.
2022-06-01
|
| 丛编: | Frontiers in Pharmacology |
| 主题: | |
| 在线阅读: | https://www.frontiersin.org/articles/10.3389/fphar.2022.829759/full |
| 标签: |
没有标签, 成为第一个标记此记录!
|